The Faces Behind Our Progress
![Joana Joana](https://www.artios.com/wp-content/uploads/2024/04/Joana-1.png)
Our Mission
Artios is committed to discovering and developing groundbreaking DDR therapeutics to help patients suffering from a broad range of devastating and difficult-to-treat cancers. Innovation in this space is part of our DNA.
Our executive officers pioneered DDR drug discovery when they co-invented the blockbuster PARP inhibitor olaparib (now marketed as Lynparza® by AstaZeneca) and led successful DDR programs while at KuDOS Pharmaceuticals, a biotechnology firm focused on oncology therapies that was acquired by AstraZeneca. Ever since, we have leveraged our deep scientific, clinical, business, and leadership expertise in DDR discovery to build a world-class platform for developing novel inhibitors of specific DNA repair enzymes. Every day, we are continually pushing the boundaries of what our novel platform can accomplish.
![artios-about- artios-about-](https://www.artios.com/wp-content/uploads/2022/01/artios-about-.png)
Advancement Through Partnership
We believe DDR-based therapies have more opportunity than we can explore alone, and we look to leverage our expertise and maximize the long-term value of our discoveries with strategic partnerships.